Xencor to Present at the 2026 Cantor Global Healthcare Conference

Xencor will webcast its September 9, 2026 Cantor Global Healthcare Conference presentation with replay access for at least 30 days.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif.--(BUSINESS WIRE)--

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.

A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor’s website located at www.xencor.com. A replay of the event will be available for at least 30 days following the presentation.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902523892/en/

Charles Liles
cliles@xencor.com
(626) 737-8118

Source: Xencor, Inc.

Key Terms

clinical-stage medical

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

engineered antibodies medical

Antibodies whose molecular structure has been deliberately modified by scientists to change how they bind targets, how long they stay active in the body, or how they trigger immune responses. Think of them as customized tools — engineered to improve potency, reduce side effects, extend dosing intervals, or make manufacturing and patent protection easier — qualities that affect a biotech product’s clinical prospects, regulatory pathway, and commercial value to investors.